{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/NTLA/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T12:44:18.893Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6732,"canonical_name":"Intellia Therapeutics, Inc.","cik":"0001652130","uei":null,"lei":null,"duns":null,"ticker":"NTLA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":31},"count":31,"timeline":[{"ts":"2026-10-06","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-10-06","url_slug":"/sec/cik-0001652130/4/0001193125-26-415541","accession_number":"0001193125-26-415541","importance":30},{"ts":"2026-10-05","kind":"sec.filing","form_type":"144","title":"144 — Intellia Therapeutics, Inc. — 2026-10-05","url_slug":"/sec/cik-0001652130/144/0001950047-26-010054","accession_number":"0001950047-26-010054","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Intellia Therapeutics, Inc. — 2026-09-08","url_slug":"/sec/cik-0001652130/8-k/0001193125-26-385194","accession_number":"0001193125-26-385194","importance":35},{"ts":"2026-09-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Intellia Therapeutics, Inc. — 2026-09-04","url_slug":"/sec/cik-0001652130/8-k/0001193125-26-383645","accession_number":"0001193125-26-383645","importance":35},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Intellia Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001652130/schedule-13g/0000093751-26-000484","accession_number":"0000093751-26-000484","importance":55},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Intellia Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001652130/10-q/0001193125-26-337952","accession_number":"0001193125-26-337952","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Intellia Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001652130/8-k/0001193125-26-336772","accession_number":"0001193125-26-336772","importance":35},{"ts":"2026-07-24","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-07-24","url_slug":"/sec/cik-0001652130/4/0001193125-26-316279","accession_number":"0001193125-26-316279","importance":30},{"ts":"2026-07-22","kind":"sec.insider.s","reporter":"Dulac Edward J III","title":"EVP, Chief Financial Officer","shares":8111,"price_per_share":11.25,"usd_value":91249,"security_title":"Common Stock","importance":35.09124875},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-07-06","url_slug":"/sec/cik-0001652130/4/0001821530-26-000002","accession_number":"0001821530-26-000002","importance":30},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-07-06","url_slug":"/sec/cik-0001652130/4/0002019493-26-000002","accession_number":"0002019493-26-000002","importance":30},{"ts":"2026-07-02","kind":"sec.form144","reporter":"EDWARD DULAC","title":"Officer","shares":4677,"usd_value":80631,"security_title":"COMMON","approx_sale_date":"2026-07-02","accession_number":"0001950047-26-006836","importance":40.016126296},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"Dulac Edward J III","title":"EVP, Chief Financial Officer","shares":4677,"price_per_share":18,"usd_value":84186,"security_title":"Common Stock","importance":35.084186},{"ts":"2026-07-02","kind":"sec.filing","form_type":"144","title":"144 — Intellia Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001652130/144/0001950047-26-006836","accession_number":"0001950047-26-006836","importance":30},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Dube Michael P","title":"VP, Chief Accounting Officer","shares":2641,"price_per_share":16.78,"usd_value":44316,"security_title":"Common Stock","importance":35.04431598},{"ts":"2026-06-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Intellia Therapeutics, Inc. — 2026-06-15","url_slug":"/sec/cik-0001652130/8-k/0001193125-26-270358","accession_number":"0001193125-26-270358","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Intellia Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001652130/8-k/0001193125-26-265934","accession_number":"0001193125-26-265934","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Verwiel Frank — 2026-06-10","url_slug":"/sec/cik-0001545794/4/0001545794-26-000001","accession_number":"0001545794-26-000001","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Goff Brian — 2026-06-10","url_slug":"/sec/cik-0001546216/4/0001193125-26-266236","accession_number":"0001193125-26-266236","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001652130/4/0001193125-26-266241","accession_number":"0001193125-26-266241","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001652130/4/0001756929-26-000002","accession_number":"0001756929-26-000002","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Intellia Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001652130/4/0001193125-26-266230","accession_number":"0001193125-26-266230","importance":30},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Cohen Fred E","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Goff Brian","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Verwiel Frank","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"CHASE WILLIAM J","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Keresty Georgia","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"GOODMAN JESSE","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Bhanji Muna","title":null,"shares":9200,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Intellia Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001652130/8-k/0001193125-26-179401","accession_number":"0001193125-26-179401","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"424B5","title":"424B5 — Intellia Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0001652130/424b5/0001193125-26-182419","accession_number":"0001193125-26-182419","importance":30}]}